EPB0220 Probability of single tablet regimens BIC/FTC/TAF, E/C/F/TAF, RPV/FTC/TAF, DTG/RPV or DTG/ABC/3TC discontinuation at 18 months in real life settings in the ANRS-CO3 - AquiVIH-NA cohortE-posterAntiretroviral therapies and clinical issues in adults
EPB0221 Cabotegravir + rilpivirine long-acting outcomes by sex at birth, age, race, and body mass index: a subgroup analysis of the Phase 3b SOLAR studyE-posterAntiretroviral therapies and clinical issues in adults
EPB0222 A Bayesian update on discontinuation of cabotegravir and rilpivirine using cohort dataE-posterAntiretroviral therapies and clinical issues in adults
EPB0223 Real-world utilization and effectiveness of long-acting cabotegravir+rilpivirine in the United States: Trio Cohort studyE-posterAntiretroviral therapies and clinical issues in adults
EPB0224 Association of oral lead-in and persistence on cabotegravir and rilpivirine long-acting in ‘real-life’E-posterAntiretroviral therapies and clinical issues in adults
EPB0225 A Site-driven CQI intervention improves advanced HIV disease screening coverage among newly diagnosed people living with HIV in MalawiE-posterAntiretroviral therapies and clinical issues in adults
EPB0226 Changes in weight and body mass index associated with dolutegravir- and non-dolutegravir-based antiretroviral treatment regimens: a longitudinal analysisE-posterAntiretroviral therapies and clinical issues in adults
EPB0227 Factors associated with viral rebound among PLHIV who achieved viral suppression in Eswatini: a retrospective cohort studyE-posterAntiretroviral therapies and clinical issues in adults
EPB0228 Towards colorimetric readout of a rapid enzymatic assay for measuring nucleotide analogs used in ART and PrEPE-posterAntiretroviral therapies and clinical issues in adults
EPB0229 High treatment continuity established among people with HIV devolved to Community Pharmacy Antiretroviral Refill Program (CPARP) in Southern NigeriaE-posterAntiretroviral therapies and clinical issues in adults
341 - 350 of 1427 items